← Leaderboards
Daniel V. Labarbera
University Of Colorado Denver
$3,658,170
Attributed
$5,564,661
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $502.1K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,564,661 · 4
By mechanism
R01$5,164,661 · 3
R42$400,000 · 1
Top collaborators
- Jonathan Mark Petrash8 shared
- Chaoping Chen3 shared
- Hector Esquer1 shared
- Neal Clifford Goodwin1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- James Christopher Costello$5,052,235
- Yuwen Zhu$3,496,594
- Christopher Hanyoung Lieu$1,848,400
- Megan L Goodall$123,629
- Mair E Churchill$8,880,598
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsLeadNovel TherapeuticsDrug DesignPropertyDesignToxic EffectPharmaceutical ChemistryValidationPharmacophoreBaseLinkGenesInhibitor/AntagonistPhenotypeEnzymesTherapeutic TargetAffinityStructureSeriesBloodMouse ModelPre-ClinicalAnimals
Grant awards (17)
CHD1Li Targeted Combinations with Chemotherapy to Address Unmet Needs in Colorectal Cancer Treatment$400,000
R42 · FY2025 · CA · contact PI
The Development of First-in-Class Inhibitors of Oncogenic CHD1L for the Treatment of Colorectal Cancer.$400,544
R01 · FY2024 · CA · contact PI
The Development of First-in-Class Inhibitors of Oncogenic CHD1L for the Treatment of Colorectal Cancer.$365,018
R01 · FY2023 · CA · contact PI
The Development of First-in-Class Inhibitors of Oncogenic CHD1L for the Treatment of Colorectal Cancer.$413,649
R01 · FY2022 · CA · contact PI
The Development of First-in-Class Inhibitors of Oncogenic CHD1L for the Treatment of Colorectal Cancer.$351,287
R01 · FY2021 · CA · contact PI
The Development of First-in-Class Inhibitors of Oncogenic CHD1L for the Treatment of Colorectal Cancer.$354,514
R01 · FY2020 · CA · contact PI
Assay Development for Identification of HIV-1 Protease Autoprocessing Specific Inhibitors$378,632
R01 · FY2018 · AI
Assay Development for Identification of HIV-1 Protease Autoprocessing Specific Inhibitors$378,605
R01 · FY2017 · AI
Assay Development for Identification of HIV-1 Protease Autoprocessing Specific Inhibitors$382,544
R01 · FY2016 · AI
Novel Therapeutics Against Diabetic Eye Disease$426,772
R01 · FY2015 · EY
Novel Therapeutics Against Diabetic Eye Disease$426,783
R01 · FY2014 · EY
Novel Therapeutics Against Diabetic Eye Disease$359,102
R01 · FY2013 · EY
Novel Therapeutics Against Diabetic Eye Disease$57,471
R01 · FY2013 · EY
Novel Therapeutics Against Diabetic Eye Disease$378,133
R01 · FY2012 · EY
Novel Therapeutics Against Diabetic Eye Disease$67,655
R01 · FY2012 · EY
Novel Therapeutics Against Diabetic Eye Disease$56,292
R01 · FY2012 · EY
Novel Therapeutics Against Diabetic Eye Disease$367,660
R01 · FY2011 · EY